Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352610 | 1.00 | MEN1 (0.63) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL18394313 | 1.00 | MEN1 (0.63) | MEN1GAAKMT2ATDP1MAOA | |
| Hydrochloric Acid SCHEMBL4433195 | 0.98 | MEN1 (0.61) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12463276 | 0.90 | MEN1 (0.73) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL12395380 | 0.90 | MEN1 (0.73) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL7195305 | 0.90 | MEN1 (0.73) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL4759987 | 0.89 | MEN1 (0.68) | MEN1GAAKMT2ATDP1MAOA | |
| Hydrochloric Acid SCHEMBL25167231 | 0.89 | MEN1 (0.71) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL3603914 | 0.89 | MEN1 (0.67) | MEN1GAAKMT2ATDP1MAOA | |
| Hydrochloric Acid SCHEMBL4989741 | 0.89 | MEN1 (0.71) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933631-A | Peptide derivative isomer, and cosmetic composition or pharmaceutical composition and use thereof | 深圳市维琪医药研发有限公司 | 2022-08-23 | — | — | CN | claimed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| WO-2025262460-A1 | LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262672-A1 | LIPID COMPOSITIONS FOR NUCLEIC ACID DELIVERY | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240376155-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-101501041-A | Amino-imidazolones and their use as medicaments for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2053403-A2 | Affinity fishing for ligands and proteins receptors | Novo Nordisk A/S (DK) | 2009-04-29 | — | — | EP | disclosed |
| EP-1797065-A4 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1588173-B1 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | NOVO NORDISK AS (DK) | 2008-11-26 | — | — | EP | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1797065-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | MEN1 2485/4885GAA 2914/4885KMT2A 2244/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | MEN1 35/4885GAA 588/4885KMT2A 3488/4885 |
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | MEN1 3420/4885GAA 254/4885KMT2A 3305/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | MEN1 1313/4885GAA 3312/4885KMT2A 4768/4885 |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | MEN1 1683/4885GAA 4570/4885KMT2A 3582/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | MEN1 3609/4885GAA 202/4885KMT2A 2826/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | MEN1 1171/4885GAA 230/4885KMT2A 2504/4885 |
| US-20240376155-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | TP53, KRAS, VHL | MEN1 195/4885GAA 1036/4885KMT2A 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.